Thomas A. MCCOURT - Feb 27, 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Feb 27, 2023
Transactions value $
-$695,523
Form type
4
Date filed
3/1/2023, 05:22 PM
Previous filing
Jan 19, 2023
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale -$292K -25.6K -3.45% $11.41 717K Feb 27, 2023 Direct F1, F2
transaction IRWD Class A Common Stock Sale -$50.3K -4.41K -0.61% $11.41 713K Feb 27, 2023 Direct F2, F3
transaction IRWD Class A Common Stock Sale -$301K -26.6K -3.74% $11.31 686K Feb 28, 2023 Direct F1, F4
transaction IRWD Class A Common Stock Sale -$51.9K -4.59K -0.67% $11.31 681K Feb 28, 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.